Key data for the approval of a nasal spray containing mometasone furoate has been obtained by the Food and Drug Administration (FDA) through the use of Malvern’s Morphologi G3-ID system.
The FDA indicated data obtained using Morphology Directed Raman Spectroscopy (MDRS) allowed them to validate the bioequivalence of the two products without the need for costly clinical endpoint bioequivalence studies.
MDRS is an analytical technique, which uses a combination of static image analysis and Raman spectroscopy to characterise the size, shape, and chemical identification of particles in a sample.
This provides the complete understanding of the characteristics of all components in a drug product including the drug substance, excipients, or any contaminant particles contained in the formulation.
It was the unique abilities of this technology which allowed the FDA to justify bioequivalence using in vitro data alone.
If you would like to learn more how the Morphologi G3-ID can assist in the characterisation of your drug product, please contact Malvern Instruments to arrange a no obligation product assessment.